Home › Calculator › OPHLY Dividend Calculator 2026
OPHLY Dividend DRIP Calculator 2026
2.69% YieldHealthcareOno Pharmaceutical Co., Ltd. · OTC
Price: $5.01 · Annual div: $0.13/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When OPHLY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your OPHLY snowball 📈
$10,000 in OPHLY → $13.36M in 10 years · $29,186.74/month
About Ono Pharmaceutical Co., Ltd. (OPHLY) — Dividend Analysis 2026
Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents. Its current portfolio features a range of established treatments, notably in oncology, with products such as the intravenous infusions OPDIVO and KYPROLIS, alongside MEKTOVI, VELEXBRU, ADLUMIZ (tablets), and BRAFTOVI (capsules) for various malignant tumors. Other specialized oncology support includes EMEND capsules and PROEMEND intravenous injections to manage chemotherapy-induced nausea and vomiting, and DEMSER capsules for symptomatic improvement in pheochromocytoma patients. Beyond cancer, Ono offers therapies for prevalent conditions like type 2 diabetes (GLACTIV and FORXIGA tablets), chronic heart failure (CORALAN), and various inflammatory and neurological disorders. Specific offerings in these areas include ONOACT injections for tachyarrhythmia, OPALMON tablets for peripheral circulatory issues, ORENCIA injections for rheumatoid arthritis, RIVASTACH patches for Alzheimer's disease, and ONGENTYS tablets for Parkinson's disease. The company also addresses needs in renal care with PARSABIV intravenous injections for dialysis patients, urological health with STAYBLA tablets for overactive bladder, and respiratory conditions with ONON capsules and dry syrups for bronchial asthma and allergic rhinitis. Furthermore, its offerings extend to musculoskeletal health with JOYCLU intra-articular injections for improving joint function, and RECALBON tablets for osteoporosis. Ono Pharmaceutical is also deeply invested in future medical advancements, with an extensive pipeline of products under development. This pipeline targets a wide array of diseases, encompassing numerous types of cancer, including esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, and myelodysplastic syndrome, as well as addressing virus positive/negative solid carcinoma. Beyond oncology, their research extends to inflammatory and autoimmune disorders such as polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy. They are also developing treatments for conditions affecting the cardiovascular and nervous systems, including tachyarrhythmia, diabetic polyneuropathy, neurodegenerative diseases, narcolepsy, and thrombosis. Established in 1717, Ono Pharmaceutical Co., Ltd. maintains its headquarters in Osaka, Japan.
Compare OPHLY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full OPHLY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open OPHLY position with:
🌍 OPHLY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold OPHLY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.69% | -0.11% | $269 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.29% | -0.51% | $229 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.15% | -0.65% | $215 / yr |
| 🇬🇧 UK ISA | 0% | 2.69% | -0.11% | $269 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.45% | -0.35% | $245 / yr |
| 🇨🇦 TFSA | 0% | 2.69% | -0.11% | $269 / yr |
| 🇨🇦 CA Taxable | 25% | 2.02% | -0.78% | $202 / yr |
| 🇦🇺 Super (pension) | 15% | 2.29% | -0.51% | $229 / yr |
| 🇦🇺 AU Taxable | 30% | 1.88% | -0.92% | $188 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.98% | -0.82% | $198 / yr |
| 🇫🇷 FR Taxable | 30% | 1.88% | -0.92% | $188 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 OPHLY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.13/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 OPHLY Dividend Payment Schedule
OPHLY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 OPHLY vs Healthcare Benchmarks
How OPHLY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OPHLY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ OPHLY Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OPHLY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ono Pharmaceutical Co., Ltd. (OPHLY) is currently trading at $5.01, 50% below its 52-week high. The current dividend yield is 2.69% based on an annual payout of $0.13 per share.
OPHLY (Ono Pharmaceutical Co., Ltd.) — 2.69% Dividend Yield Analysis
Ono Pharmaceutical Co., Ltd. (OPHLY) is a healthcare stock currently trading at $5.01 with a dividend yield of 2.69%. The company pays an annual dividend of $0.13 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, OPHLY has grown its dividend at a compound annual rate of 100.0%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.